Levosimendan in aortic valve surgery: cardiac performance and recovery

Area of Science:

• Cardiology
• Cardiac Surgery
• Pharmacology

Background:

• Severe aortic stenosis (AS) and left ventricular (LV) hypertrophy can impair cardiac performance.
• Myocardial stunning and low output are common complications after cardiopulmonary bypass.
• Vasoactive medications are often required to manage cardiac function during and after surgery.

Purpose of the Study:

• To evaluate the effects of levosimendan on cardiac performance in patients with severe AS and LV hypertrophy undergoing cardiac surgery.
• To determine if levosimendan reduces the need for other vasoactive medications postoperatively.

Main Methods:

• A prospective, randomized, double-blind, placebo-controlled study.
• Twenty-four patients with severe AS and LV hypertrophy were enrolled.
• Twelve patients received a 24-hour levosimendan infusion, while 12 received a placebo.

Main Results:

• Left ventricular ejection fraction was initially lower in the levosimendan group but was maintained postoperatively, unlike in the placebo group.
• The levosimendan group required more norepinephrine intraoperatively but less nitroprusside postoperatively.
• Venous saturations normalized in the levosimendan group after infusion initiation.

Conclusions:

• Levosimendan may prevent a critical drop in LV function after cardiopulmonary bypass in patients with severe AS and LV hypertrophy.
• The vasodilatory effect of levosimendan can be managed with norepinephrine.
• Levosimendan shows potential as a beneficial adjunct in specific cardiac surgical populations.